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Treatment of L1210 cells with prostaglandin A2 (PGA*) or 9-deoxy-&‘*-13,14_dihydro PGD2 (d”-PGJa resulted in significant GUM arrest and 
subsequent DNA fragmentation at concentrations that are cytotoxic to the cells. On agarose gel electrophoresis, DNA ladder formation was evident 
24 h after the addition of d”-PGJ, and remained apparent hrough 72 h, whereas G2/M accumulation was observed 6 h after the treatment. When 
the morphology of cells was examined by electron microscopy, L1210 cells incubated with a cytotoxic dose of PGA2 or di2-PGJz for 24 h showed 
the characteristic morphological features of apoptosis such as chromatin condensation, nuclear fragmentation and formation of apoptotic body. 
Cycloheximide blocked the DNA fragmentation and morphological changes induced by d’*-PGJ,. Our results suggest hat these cyclopentenone 
PCs caused apoptotic cell death of L1210 cells which is preceded by G2/M accumulation and requires de novo protein synthesis. 
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1. INTRODUCTION 
Cyclopentenone prostaglandins (PGs) such as PGA, 
and 9-deoxy-A 9J2- 13,14_dihydro PGD, (A’*-PGJ2) have 
potent antiproliferative activity on various cultured 
tumor cells [l-3]. It has been shown that these PGs 
block cell progression from the Gl to S phase [4]. Re- 
cently, Narumiya and coworkers reported that these 
PGs are actively transported into cells by a specific 
carrier on the cell surface and accumulated in the nuclei 
and that this uptake and accumulation are closely re- 
lated to their growth inhibitory activity [5-71. But the 
precise molecular mechanism by which these PGs exert 
cytostatic or cytotoxic activity remains unclarified. 
cyclopentenone PGs, we examined the effects of these 
PGs on the DNA integrity, the ultrastructural morphol- 
ogy and cell cycle progression in L1210 cells. Our study 
revealed that these PGs lead to cell death via en- 
dogenous apoptotic pathway which is preceded by G21 
M arrest and requires continued protein synthesis. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Apoptosis is a controlled process of cell death which 
is involved in various physiological conditions including 
normal cell turnover, hormone-induced tissue atrophy, 
embryological development and effector cell mediated 
target cell lysis [&lo]. It is also observed in toxin-in- 
duced cell lysis and in vitro tumor cell death by cytoki- 
nes such as tumor necrosis factor (TNF) and transform- 
ing growth factor-j? (TGF-/3) [ 1 l-l 31. The cells undergo- 
ing apoptosis showed characteristic morphological fea- 
tures [ 141 and internucleosomal DNA cleavage yielding 
fragments in multiples of 180 bp, called ladder DNA, 
on agarose gel electrophoresis [ 151. 
PGA2, D2 and E2 were purchased from Sigma (St. Louis, MO) and 
d”-PGJ2 was kindly provided by Ohno Pharmaceutical Company 
(Osaka, Japan). The DNA size marker (123 ladder DNA) was ob- 
tained from BRL (Bethesda, MD) and all other reagents were of 
analytical grade. 
2.2. Assay of antiproliferative activity 
L1210 murine leukemia cells were obtained from American Type 
Culture Collection (ATCC, Rockville, MD) and cultured in RPM1 
1640 medium supplemented with 10% heat-inactivated fetal calf serum 
and 50 &ml of gentamicin. Cells were plated at a density of 5 x 1OYml 
in 24-well culture plate and incubated with various concentrations of 
PGA, and d’2-PGJ2. The number of viable cells was counted daily by 
Trypan blue exclusion test. 
2.3. Gel electrophoresis and measurement of fragmented DNA 
DNA fragmentation in L1210 cells was analyzed after the cells 
To investigate the mechanism for cytotoxic activity of 
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(2 x lO?dish) were treated with PGA, or d12-PGJ2 for indicated times. 
In some experiments, cells were preincubated with cycloheximide (up 
to 0.5 pug/ml) or actinomycin-D (2 @ml) for 1 h before the addition 
of dr2-PGJ2. Cells were lysed in lysis buffer (500 mM Tris-HCl (pH 
9.0), 2 mM EDTA, 10 mM NaCl, 1% (w/v) SDS)) and treated with 
proteinase K (1 mglml) for 2-8 h as described by Kaufmann et al. 
[16]. DNA was extracted and 5 &ml of DNA was analyzed by 1% 
agarose gel electrophoresis as described [17]. DNA was visualized by 
staining with ethidium bromide (10 pg/ml) under UV light. 
Abbreviations: PC, prostaglandin; A’*-PGJ,, 9-deoxy-d9.‘2-13,14-dihy- DNA fragmentation was also quantitated by measuring soluble 
dro PGD,; TNF, tumor necrosis factor; TGF-p, transforming rowth DNA fragments after cell lysis. After incubation of d12-PGJ2 for 48 h, 
factor-/I. cells were lysed, centrifuged at 13,000 x g for 10 min and the amount 
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of DNA in both the pellet (intact DNA) and the supernatant (DNA 
fragments) was measured by using the diphenylamine reagent [18]. 
Calf thymus DNA was used as a standard. Fragmentation was calcu- 
lated as percentage of DNA recovered in the supernatant as described 
previously [ 191. 
2.4. Examination of cell morphology 
L1210 cells treated with PGA2 or d’2-PGJ2 for 24 h were processed 
for electron microscopic examination as described by Reynold et al. 
[20]. The ultrathin sections were mounted on nickel grids, stained with 
uranyl acetate and lead citrate and photographed with a JEOL type 
1200 EX (Tokyo, Japan) electron microscope at an accelerating volt- 
age of 80 kV. 
2.5. Flow cytometric analysis 
To determine the effect of PGA, or d”-PGJ, on the cell cycle 
progression of L1210 cells, cells were isolated at indicated times fol- 
lowing treatment and analyzed using DNA reagent kit, Cycle TEST, 
obtained from B&on-Dickinson (San Jose, CA) and Coulter Epics 
profile II Flow cytometer (Hialeah, FL). 
3. RESULTS 
In our preliminary test, L1210 cells showed cytotoxic 
response to PGA2 and d1’-PGJ2 at a concentration of 
10 lug/ml and 2.0 @ml, respectively. Incubation of 
L1210 cells with cytotoxic concentration of PGA, or 
di2-PGJ2 resulted in extensive degradation of DNA. As 
shown in Fig. 1, electrophoresis of total cellular DNA 
from PGA2 or d”-PGJ, treated L1210 cells revealed a 
typical ladder pattern of DNA fragments consisting of 
multiples of 180 bp. In non-treated control cells DNA 
fragmentation was not observed, while DNA from ne- 
crotic cells showed smear pattern of random degrada- 
tion. 
Fig. 2. Time course of DNA fragmentation i  L1210 cells by A’*-PGJz. 
L1210 cells were incubated with 2.5&ml ofA’*-PGJ, for 0,6, 12,24, 
48, or 72 h (lanes 2-8, respectively). At indicated times, DNA was 
isolated and analyzed as described in Fig. 1. Lane 1 represents a 123 
bp DNA ladder as marker. 
dehydration product of PGE2 and PGD,, respectively 
[3,12]. The cytotoxic activity of PGE, and PGD, ap- 
peared at higher concentrations. When examining the 
effect of PGE, and PGD, on DNA degradation, inter- 
nucleosomal DNA cleavage was also caused by a cyto- 
toxic concentration of these PGs in L1210 cells (data 
not shown). 
PGA2 and d”-PGJ, are known to be the enzymatic Typical ladder pattern became evident 24 h after the 
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Fig. 1. Electrophoretic analysis of DNA from L1210 cells treated with 
PGA, or A’*-PGJ2. L1210 cells were incubated without (lane 2) or with 
10 fig/ml of PGA, (lane 4) or 2.5 &ml of A’*-PGJ2 (lane 5) for 48 h. 
5 pg of DNA from each sample was analyzed on 1% agarose gel 
electrophoresis as described in section 2. For comparison, DNA from 
necrotic cells incubated for 72 h after heating for 30 min at 56°C was 
shown in lane 3. Lane 1 is a 123 bp DNA ladder as marker. 
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Fig. 3. DNA fragmentation i  L1210 cells treated with various concen- 
trations of d’2-PGJz. Cells were treated O-5 @ml of A’*-PGJ, for 48 
h and the cell lysate was centrifuged at 13,080 x g for 10 min. DNA 
fragmentation was determined by measuring DNA in the supematant 
and the pellet with diphenylamine reagent. Experiments were done in 
triplicate. 
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treatment of d”-PGJ, and persisted for up to 72 h (Fig. 
2). 
The quantitative analysis of DNA fragmentation in- 
duced by d12-PGJ2 is shown in Fig. 3. With 1 &ml of 
A”-PGJ2, which only shows a growth inhibitory effect 
rather than a cytotoxic effect, there was no difference 
in the percentage of fragmented DNA as compared with 
the control. The content of fragmented DNA was signif- 
icantly increased in cells treated with a cytotoxic dose 
of d12-PGJ2 (a 2 @g/ml), reached maximum at 3 @ml 
and decreased at higher concentrations. 
One of the interesting features of apoptosis is its de- 
pendency on the active synthesis of proteins under 
many circumstances [19,21]. So we investigated whether 
cycloheximide, known to affect apoptosis, can protect 
L1210 cells against d”-PGJ,-induced cytotoxic process. 
Fig. 4A shows that 0.5 pg/ml of cycloheximide adminis- 
tered 1 h before the addition of A”-PGJ2 completely 
blocked DNA fragmentation. Actinomycin-D at 2 ng/ 
ml concentration did not inhibit DNA fragmentation. 
Higher concentrations of actinomycin-D could not be 
tested because actinomycin-D alone caused DNA frag- 
mentation (data not shown). Using the diphenylamine 
assay, we also observed that the percentage of frag- 
mented DNA gradually decreased to control levels by 
increasing the concentration of cycloheximide up to 0.5 
,@rnl, indicating that protein synthesis is essential for 
the induction of DNA fragmentation by d12-PGJ2 (Fig. 
4B). 
We then examined the morphological changes in- 
duced by PGA, or d12-PGJ, by electron microscopy to 
confirm the apoptotic nature as suggested by the pre- 
ceding findings. The L1210 cells treated with PGA, or 
d12-PGJ2 for 24 h showed convolution of the nuclear 
membrane, fragmentation of the nucleus and formation 
of apoptotic body (Fig. 5A), and chromatin condensa- 
tion, membrane blebbing and marked vacuolization 
(Fig. 5B), which are typical morphological features of 
apoptosis. But the cells treated with cycloheximide 
failed to show such findings representative of apoptosis 
(data not shown). 
Next, we performed cell cycle analysis in order to 
determine whether the changes in cell cycle progression 
are associated with the antiproliferative activity of these 
PGs in L1210 cells. As shown in Fig. 6, the cells treated 
with a growth inhibitory dose of di2-PGJ2 (1 pg/rnl) 
showed G2/M accumulation at 18 h after initiating the 
treatment, and then cells were released from this block- 
age and returned to almost normal levels at 48 h of 
incubation. But the treatment of L1210 cells with a 
cytotoxic dose of d12-PGJ, (2 @ml) caused more pro- 
found and persistent G2/M arrest which was evident at 
6 h and at a maximum at 18 h following the treatment. 
PGA, also caused L1210 cells to be blocked at the G2/ 
M phase (data not shown). Since only the cells which 
have intact DNA were analyzed in our cell cycle study 
and DNA fragmentation was evident at 24 h after the 
1107 - 
861 - 
615 - 
492 - 
369 - 
246 - 
123 - 
Ocontrol b 
Cyclohexhride ( &g/ml 1 
Fig. 4. Inhibition of DNA fragmentation by cycloheximide. (A) L1210 
cells were preincubated for 1 h without pretreatment (lane 3), with 0.5 
,~g/ml of cycloheximide (lane 4), or with 2 &ml of actinomycin-D 
(lane 5). After 48 h of additional incubation with 2.5 &ml of A’*- 
PGJ2, cells were lysed and DNA was analyzed by agarose gel electro- 
phoresis as described in Fig. 1. Lane 1 is marker and lane 2 is DNA 
from control cells. (B) Cells were pretreated with various concentra- 
tions of cycloheximide for 1 h and further incubated for 48 h in the 
presence of 2.5 &ml of A’*-PGJ2. DNA fragmentation was quantita- 
tively determined using diphenylamine reagent as described in Fig. 3. 
treatment (Fig. 2), the decrease in the cell proportion of 
the G2/M phase and concomitant increase of Gl phase 
cells observed after 24 h (Fig. 6C) might be due to the 
subsequent DNA degradation of G2/M arrested cells, 
not due to the actual progress to the Gl phase. Incuba- 
tion of L1210 cells with 0.5 &ml of cycloheximide 1 h 
prior to the treatment with d12-PGJ2 inhibited the accu- 
mulation of cells at the G2/M phase (Fig. 6D) whereas 
actinomycin-D had no effect on the cell cycle arrest 
induced by d12-PGJ, (data not shown). 
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Fig. 5. Electron micrographs of PGA, or A”-PGJ2 treated L1210 cells. Cells were treated with 10 @ml of PGA, (a) or 2.5 @ml of d’*-PGJ, 
(b) for 24 h and prepared for electron microscopic examination as described in section 2. Bars, 1 pm. 
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Fig. 6. Effect of d’*-PGJ2 on the cell cycle progression of L1210 cells. 
The flow cytometric patterns were determined at indicated times after 
the treatment as described in section 2. Treatments as follows: A, 
control; B, 1 &ml of k2-PGJ,; C, 2 ,ug/ml of d”-PGJ2; D, 0.5 ,ug/ml 
of cycloheximide 1 h prior to the addition of 2 @ml of d”-PGJ2. 
4. DISCUSSION 
In the present study, we demonstrate that the L1210 
cells incubated with a cytotoxic dose of PGA, or A”- 
PGJ2 showed many of the cardinal signs of apoptosis, 
indicating that cytotoxicity induced by these PGs is me- 
diated via an endogenous apoptotic pathway. Recently, 
cytokines such as TNF and TGF-B, and several cancer 
chemotherapeutic agents were reported to induce apop- 
tosis of cultured tumor cells in different systems 
[12,13,16]. So, apoptosis appears to be a significant 
process of cell death in tumor regression as well as in 
physiological condition. 
Little is known about the intracellular signal pathway 
for apoptosis. Possible signaling mechanisms in the ini- 
tiation of apoptosis include the influx of Ca*’ ions, a 
change of protein kinase C (PKC) activity and altered 
expression of the oncogenes c-for and c-r;lyc [22-241. 
Also the agents that elevate CAMP levels in the cells, 
including PGE,, induced apoptosis in thymocytes [25]. 
But the increase in CAMP levels does not seem to act as 
a signal for apoptosis in our experiments because PGA, 
and di2-PGJ2 appeared to be ineffective in activating 
adenylate cyclase [2,26]. In this report, we demonstrate 
that A’*-PGJ2 arrested L1210 cells at the GUM phase 
in the cell cycle progression before the appearance of 
DNA fragmentation on agarose gel electrophoresis 
(Fig. 2), while Gl phase arrest was reported as the 
major basis for antiproliferative activities of these PGs 
in other tumor cell lines such as HeLa and GOT0 cells 
[4,27,28]. G2 arrest is known as a cellular response to
DNA damage to prevent cells entering the mitotic phase 
prior to the repair of damaged DNA [29-321. Therefore, 
DNA seems to be the primary target for A’*-PGJ2-in- 
duced cytotoxicity in L1210 cells, leading to G2/M ar- 
rest in cell cycle progression. It can be postulated that 
a non-toxic dose of A’*-PGJ2 causes reversible G2 arrest 
during which DNA damage can be repaired and cells 
continue to progress in their cell cycle, but toxic concen- 
tration of d12-PGJ, induce lethal DNA damage resulting 
in persistent G2 arrest and these cells subsequently die 
through the process of apoptosis. This is consistent with 
the idea that the morphological changes observed in the 
cells undergoing apoptosis are related to events that 
normally occur at G2 to M transition such as chromatin 
condensation and membrane breakdown, as suggested 
by Sorenson et al. [33]. 
The association of G2 arrest and subsequent DNA 
degradation or cell death has already been demon- 
strated in several tumor cell lines, including L 1210 cells, 
exposed to various chemotherapeutic agents [33-361. 
However, the molecular mechanism initiating the se- 
quence of cellular events which lead the G2 arrested 
cells to death remains unclear. Lock and Ross proposed 
that, in etoposide-treated CHO cells, perturbations in 
the activity of ~34~‘~ kinase, which is essential for pas- 
sage of cells into mitosis [37], are related to transient G2 
arrest and following irregular chromosome fragmenta- 
tion with a concomitant progress to mitosis [38,39]. Pre- 
mature chromosome condensation and nuclear mem- 
brane breakdown are also observed when S phase-ar- 
rested BHK cells are artificially driven into mitosis by 
caffeine [40]. In addition, it has been shown that cyto- 
toxic effects of cell cycle phase-specific agents resulted 
from the dissociation of normally coupled cell cycle 
progression events [41]. Therefore, it will be necessary 
to investigate the role of cell cycle-regulatory proteins 
in the A’*-PGJ,-induced G2/M arrest which is followed 
by apoptotic cell death. 
Our results also showed that cycloheximide blocked 
the induction of apoptosis caused by A’*-PGJ,. This is 
compatible with the results of previous studies that cy- 
cloheximide reduced A’*-PGJ, cytotoxicity on NCH 
human neuroblastoma cells and KSu osteosarcoma 
[36,42], indicating the requirement of continued protein 
synthesis for cytotoxicity of A’*-PGJ2. In this context, 
decrease of DNA fragmentation observed at high (> 3 
213 
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@nl) concentration of A’*-PGJ2 (Fig. 3) might be the 
result of nonspecific inhibition of protein synthesis 
which occurred at these concentration of A’*-PGJ2. Fur- 
thermore, cycloheximide also reduced G2/M accumula- 
tion induced by A’*-PGJ2, which seems to be a prerequi- 
site for apoptosis, suggesting that suppression of cell 
cycle progression by cycloheximide as well as protein 
synthesis inhibition contribute the protective effect of 
cycloheximide against A’*-PGJ2-induced apoptosis. Sev- 
eral groups reported that specific proteins, including 
heat shock proteins, were induced in cells treated with 
these cyclopentenone PGs [28,43&l]. It is not certain, 
however, whether these PG-induced proteins are in- 
volved in the apoptotic pathway or in the regulation of 
cell cycle progression in L1210 cells. And the relevance 
of these PG-induced proteins to the gene products such 
as transglutaminase and TRPM-2 (testosterone-re- 
pressed prostate message-2) [45,46], known to be in- 
creased in apoptosis, is also to be determined. 
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